253 related articles for article (PubMed ID: 27061975)
1. Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group.
Crespo M; Navarro J; Moreno S; Sanz J; Márquez M; Zamora J; Ocampo A; Iribaren JA; Rivero A; Llibre JM
Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):493-498. PubMed ID: 27061975
[TBL] [Abstract][Full Text] [Related]
2. Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents.
Rockstroh JK; Soriano V; Plonski F; Bansal M; Fätkenheuer G; Small CB; Asmuth DM; Pialoux G; Mukwaya G; Jagannatha S; Heera J; Pineda JA
HIV Clin Trials; 2015; 16(2):72-80. PubMed ID: 25923596
[TBL] [Abstract][Full Text] [Related]
3. Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program.
Lazzarin A; Than S; Valluri SR; Heera J; Mukwaya G
HIV Clin Trials; 2012; 13(2):83-9. PubMed ID: 22510355
[TBL] [Abstract][Full Text] [Related]
4. More improvement than progression of liver fibrosis following antiretroviral therapy in a longitudinal cohort of HIV-infected patients with or without HBV and HCV co-infections.
Ding Y; Duan S; Ye R; Yang Y; Yao S; Wang J; Cao D; Liu X; Lu L; Jia M; Wu Z; He N
J Viral Hepat; 2017 May; 24(5):412-420. PubMed ID: 27925409
[TBL] [Abstract][Full Text] [Related]
5. HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
Su S; Fairley CK; Sasadeusz J; He J; Wei X; Zeng H; Jing J; Mao L; Chen X; Zhang L
J Med Virol; 2018 Mar; 90(3):518-525. PubMed ID: 29091279
[TBL] [Abstract][Full Text] [Related]
6. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
Pembroke T; Deschenes M; Lebouché B; Benmassaoud A; Sewitch M; Ghali P; Wong P; Halme A; Vuille-Lessard E; Pexos C; Klein MB; Sebastiani G
J Hepatol; 2017 Oct; 67(4):801-808. PubMed ID: 28527666
[TBL] [Abstract][Full Text] [Related]
7. HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study.
Bailey H; Nizova N; Martsynovska V; Volokha A; Malyuta R; Cortina-Borja M; Thorne C;
BMC Infect Dis; 2016 Dec; 16(1):755. PubMed ID: 27955711
[TBL] [Abstract][Full Text] [Related]
8. Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection--The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index.
Rollet-Kurhajec KC; Moodie EE; Walmsley S; Cooper C; Pick N; Klein MB;
PLoS One; 2015; 10(6):e0129868. PubMed ID: 26090666
[TBL] [Abstract][Full Text] [Related]
9. Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir.
Palacios R; Vergara S; Rivero A; Aguilar I; Macías J; Camacho A; Lozano F; García-Lázaro M; Pineda JA; Torre-Cisneros J; Márquez M; Santos J
HIV Clin Trials; 2006; 7(6):319-23. PubMed ID: 17197379
[TBL] [Abstract][Full Text] [Related]
10. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
[TBL] [Abstract][Full Text] [Related]
11. Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.
Boyd A; Bottero J; Miailhes P; Lascoux-Combe C; Rougier H; Girard PM; Serfaty L; Lacombe K
J Int AIDS Soc; 2017 Feb; 20(1):21426. PubMed ID: 28362068
[TBL] [Abstract][Full Text] [Related]
12. Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.
Gonzalez FA; Van den Eynde E; Perez-Hoyos S; Navarro J; Curran A; Burgos J; Falcó V; Ocaña I; Ribera E; Crespo M
HIV Med; 2015 Apr; 16(4):211-8. PubMed ID: 25234826
[TBL] [Abstract][Full Text] [Related]
13. Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial.
Rockstroh JK; Plonski F; Bansal M; Fätkenheuer G; Small CB; Asmuth DM; Pialoux G; Zhang-Roper R; Wang R; Pineda JA; Heera J
Antivir Ther; 2017; 22(3):263-269. PubMed ID: 27924779
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival.
Chen M; Wong WW; Law MG; Kiertiburanakul S; Yunihastuti E; Merati TP; Lim PL; Chaiwarith R; Phanuphak P; Lee MP; Kumarasamy N; Saphonn V; Ditangco R; Sim BL; Nguyen KV; Pujari S; Kamarulzaman A; Zhang F; Pham TT; Choi JY; Oka S; Kantipong P; Mustafa M; Ratanasuwan W; Durier N; Chen YM
PLoS One; 2016; 11(3):e0150512. PubMed ID: 26933963
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients.
Fernández-Montero JV; Vispo E; Barreiro P; Sierra-Enguita R; de Mendoza C; Labarga P; Soriano V
Clin Infect Dis; 2014 Jun; 58(11):1549-53. PubMed ID: 24633686
[TBL] [Abstract][Full Text] [Related]
16. Acute liver enzyme elevations in HIV-1-infected patients.
Livry C; Binquet C; Sgro C; Froidure M; Duong M; Buisson M; Grappin M; Quantin C; Portier H; Chavanet P; Piroth L
HIV Clin Trials; 2003; 4(6):400-10. PubMed ID: 14628283
[TBL] [Abstract][Full Text] [Related]
17. The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi.
Andreotti M; Pirillo MF; Liotta G; Jere H; Maulidi M; Sagno JB; Luhanga R; Amici R; Mancini MG; Gennaro E; Marazzi MC; Vella S; Giuliano M; Palombi L; Mancinelli S
BMC Infect Dis; 2014 Apr; 14():180. PubMed ID: 24708626
[TBL] [Abstract][Full Text] [Related]
18. Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.
Clotet B; Clumeck N; Katlama C; Nijs S; Witek J
J Antimicrob Chemother; 2010 Nov; 65(11):2450-4. PubMed ID: 20801782
[TBL] [Abstract][Full Text] [Related]
19. Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population.
Yu G; Chi X; Wu R; Wang X; Gao X; Kong F; Feng X; Gao Y; Huang X; Jin J; Qi Y; Tu Z; Sun B; Zhong J; Pan Y; Niu J
PLoS One; 2015; 10(9):e0139015. PubMed ID: 26422607
[TBL] [Abstract][Full Text] [Related]
20. Delayed liver fibrosis in HTLV-2-infected patients co-infected with HIV-1 and hepatitis C virus with suppressive antiretroviral therapy.
Abad-Fernández M; Moreno A; Dronda F; del Campo S; Quereda C; Casado JL; Pérez-Elías MJ; Moreno S; Vallejo A
AIDS; 2015 Feb; 29(4):401-9. PubMed ID: 25565497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
